MONTREAL and CHARLOTTE, N.C., Sept. 27, 2023 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (MIST) today announced that results from a double-blind, randomized, placebo-controlled Phase 2 etripamil ...
Etripamil, an investigational drug, showed statistically significant reduction in ventricular rate by 30 beats per minute for episodes of atrial fibrillation with rapid ventricular rate (p 0.0001) ...
Atrial fibrillation, or AFib, is the most common type of arrhythmia in adults. A heart arrhythmia is when your heartbeat has an abnormal rate or rhythm. This can mean it beats too slowly, too quickly, ...
MONTREAL and CHARLOTTE, N.C., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today reported financial results for the third quarter ending September 30, 2025, and ...
- Self-administration of etripamil in patients experiencing AFib-RVR episodes resulted in a substantial reduction in ventricular rate which was sustained over 60 minutes - Data featured in an oral ...
MONTREAL and CHARLOTTE, N.C., Nov. 7, 2023 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (MIST) today announced that the Company will host a virtual investor and analyst webcast on Monday, November ...
Milestone Pharmaceuticals ( ($MIST) ) just unveiled an update. Milestone Pharmaceuticals announced its third-quarter financial results and ...
MONTREAL and CHARLOTTE, N.C., March 29, 2021 /CNW/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback